Aviceda Announces Podium Presentations on AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, at American Society of Retina Specialists (ASRS) and the OIS Retina Innovation Summit Meetings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private late clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to alleviate chronic non-resolving inflammation, announces upcoming presentations about its lead ophthalmic clinical asset, AVD-104, a novel glycan-coated nanoparticle for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

“We are excited about Aviceda's presence at ASRS this year. AVD-104 was engineered with dual mechanism of action to target both the cellular immune dysfunction and complement implicated in AMD progression. “We look to usher in a new paradigm for safer and effective treatment of GA associated with AMD,” said Mohamed Genead, M.D., Chief Executive Officer & Co-Founder, Aviceda Therapeutics.

• July 27, 2023 – OIS Retina Innovation Summit, Seattle, WA
  • Title: AVD-104, A Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration
  • Presenter: Tarek S. Hassan, M.D., Chief Development Officer, Aviceda Therapeutics.

• July 29, 2023 – American Society of Retina Specialists Annual Meeting, Seattle, WA
  • Title: Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Using New Sialic Acid–Coated Nanoparticles
  • Presenter: Carl D. Regillo, M.D., Professor of Ophthalmology at Thomas Jefferson University, Chief of the Retina Service of Wills Eye Hospital, and Aviceda’s clinical advisory board member.

“I am excited to present the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104. This drug may the first next generation treatment for GA with its dual mechanisms of action that attack critical inflammatory pathways by inhibiting activated retinal macrophages and repolarizing them to their resolution states while also inhibiting amplification of the complement cascade,” said Dr. Regillo.

Visit https://www.clinicaltrials.gov/search?cond=NCT05839041 to learn more about the SIGLEC trial.

About Aviceda Therapeutics and AVD-104

Aviceda is a private clinical-stage biotechnology company located in Cambridge, MA, with a proprietary HALOS™ nanotechnology platform and an IND-cleared ophthalmic lead product for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is an intravitreal nanoparticle molecule with a promising dual mechanism of action for the treatment of GA through its modulation of critical inflammatory & complement pathways: 1) Direct inhibition of the activity of damaging phagocytic macrophages and repolarization of activated macrophages to their resolution state, and 2) inhibition of complement cascade amplification. AVD-104 has demonstrated robust in-vitro/vivo efficacy with inhibition of both inflammatory & complement pathways and the potential for every 3- to 6-month dosing. Outstanding safety has been demonstrated in multiple animal models, including non-human primates, in which no signs of intraocular inflammation were seen. In addition, AVD-104 has demonstrated anti-neovascular activity equivalent to that of aflibercept (Eylea) in a well-established ocular CNV model. SIGLEC Phase 2/3 clinical trial is currently actively enrolling for GA in US.

Along with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including neurology, oncology, fibrosis, and immunology.

Learn more about Aviceda Therapeutics.

Aviceda Therapeutics Inc.
info@avicedarx.com